Fondazione Melanoma Onlus
7 clinical trials · Sponsor
◉ Watch Fondazione Melanoma Onlus
| Record | Firm | Date |
|---|---|---|
| Study to Evaluate Impact® as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma (NCT06880198) | Fondazione Melanoma Onlus | 2024-08-01 |
| "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)" (NCT05299580) | Fondazione Melanoma Onlus | 2021-02-18 |
| Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma (NCT04632433) | Fondazione Melanoma Onlus | 2021-02-10 |
| Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (NCT04722575) | Fondazione Melanoma Onlus | 2020-12-03 |
| Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients (NCT03224208) | Fondazione Melanoma Onlus | 2018-05-17 |
Track Fondazione Melanoma Onlus automatically
Every clearance here is in the API, with alerts when new ones post.